Healthcare
OPKO Health, Inc.(OPK)
Live Price
Offline$1.43
+0.70% today
1Y Change
+9.45%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $830.00M
- Revenue Growth
- -14.9%
- EPS Growth
- -291.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OPKO Health, Inc. (OPK) is a Healthcare stock with a market cap of $830.00M and listed on NASDAQ. The stock last traded around $1.43 and up 9.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -14.9%, EPS growth of -291.1%, a dividend yield of 0.0%. What stands out right now is revenue -14.9%, EPS -291.1%, free cash flow +8.5% with operating margin -34.9% and ROIC -10.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OPK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-14.9% vs +7.6% peer median
Operating Margin
Below sector median
-34.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -14.9% and EPS is at -291.1%, with operating margin around -34.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +1.8% | +0.9% | +28.8% |
2026 Feb 26, 2026 | +42.9% | +0.0% | -2.5% | -2.5% |
2025 Oct 29, 2025 | +250.0% | +2.1% | -6.3% | -6.3% |
Benchmark Edge
OPK vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OPK
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OPK Max Drawdown
-30.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OPK and SPY.
Company Overview
OPKO Health, Inc.
NASDAQ Global Select
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
- Leadership
- Phillip Frost
- IPO Date
- Nov 2, 1995
- Employees
- 3.0k
- Street Address
- 4400 Biscayne Boulevard
- Mailing
- Miami, FL, 33137
- Region
- Miami, FL, US
- Reporting Currency
- USD
- Investor Line
- 305 575 4100
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.4
- Price/Book
- 0.7
Growth
- Revenue
- -14.9%
- EPS
- -291.1%
- Free Cash Flow
- +8.5%
Profitability
- Gross Margin
- 22.7%
- Operating Margin
- -34.9%
- Net Margin
- -36.6%
- ROE
- -16.8%
- ROIC
- -10.9%
Balance Sheet
- Debt/Equity
- 0.33
- Current Ratio
- 3.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.